Expect mergers and acquisition action, albeit for “smaller assets,” by Dr. Reddy's Laboratories Ltd. - the front-line Indian firm appears set to seal a deal or so sometime soon, if all goes per plan, going by senior management commentary at its fiscal third quarter earnings announcement.
Acquisitions, Mix-Match Sputnik Light Booster On Dr Reddy’s Menu
Dr Reddy’s indicates it is actively pursuing acquisitions, likely involving relatively smaller assets, across several key markets on the back of a “healthy” balance sheet. It is also progressing plans to position Russian COVID-19 vaccine Sputnik Light as a booster, which it believes could potentially be “part of life” hereon.
More from Business
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.